CVRx’s baroreflex activation therapy (BAT) technology can potentially treat heart failure for millions of patients without taking up precious real estate within the heart, CEO Nadim Yared explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Nadim sits down with BI analyst Matt Henriksson for an in-depth interview about the company, including recent developments in BAT and how its Barostim NEO, an implantable pulse generator, works for heart-failure patients even though it’s placed away from the organ.
See omnystudio.com/listener for privacy information.
Vanguards of Health Care by Bloomberg Intelligence